Oramed’s Letter to Shareholders
NEW YORK, Feb. 20, 2024 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron. Dear Shareholders, I am pleased to share with you an update regarding Oramed. Despite the […]
Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China
Oramed has completed an analysis of its U.S. -based Phase 3 oral insulin trial with significant lowering of A1C levels seen in patient subgroups NEW YORK , May 15, 2023 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ) announced today that Hefei Tianhui
Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism
NEW YORK , Nov. 29, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Diabetes, Obesity, and Metabolism, has published an original
About
About Us Oramed Pharmaceuticals (NASDAQ: ORMP) was established in 2006 and has developed a unique proprietary platform technology that allows for the oral delivery of drugs presently administered only via injection. Oramed has an experienced management team with many years of business and pharmaceutical experience and is backed by world-class scientific experts. Oramed’s flagship product, […]
SABC News: An oral drug delivery system for Diabetes insulin on the horizon
CEO Nadav Kidron spoke to SABC News’ First Take about the potential of oral insulin. SABC writes: “There is good news beckoning on the horizon. Oramed Pharmaceuticals a biotechnology company based in the United States and Israel is developing an oral drug delivery system aptly named Oramed’s oral insulin. This could be the first oral […]
Oramed’s Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients
91% of T1D patients and 85% of T2D patients surveyed indicated they were “extremely likely” or “very likely” to ask their doctors about ORMD-0801 NEW YORK, Sept. 15, 2020 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results […]
Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board
NEW YORK, Jan. 23, 2020 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the addition of Dr. Alexander Fleming to its Scientific Advisory Board. Dr. Fleming is Founder and Executive Chairman of Kinexum. Dr. Fleming previously held various positions at […]
i24news: New technology could revolutionize market of 500 million diabetes patients
CEO Nadav Kidron speaks with i24 News about the potential of oral insulin. Read and Watch here.
Oramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes
Achieves primary endpoint with statistically significant reduction in A1C versus placebo Excellent safety profile Conference call today at 8:30 a.m. ET to review Phase IIb data; Extended review event and conference call scheduled for November 18th NEW YORK, November 12, 2019 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused […]
Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801
Topline data readout expected Q4 2019 NEW YORK, Sept. 17, 2019 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the treatment of the last patient in the primary cohort of the Phase IIb HbA1c trial evaluating Oramed’s lead oral insulin […]
